In recognition of our success in active pharmaceutical ingredients (APIs) process development, Tokuyama Corporation (hereinafter referred to as "the Company" or "Tokuyama") has won the Excellence in Pharma Award in the category of API Development at CPhI Worldwide held in Frankfurt, Germany for three days starting on November 1, 2022.

Since 2004, the CPhI Pharma Awards have been offered to technologies that contribute significantly to the development of pharmaceutical science and technologies. This year, there were approximately 180 entries in 10 categories.

The winning innovation is "Novel Synthesis of SGLT2 Inhibitors", which relates to an innovative process development for diabetes drugs conducted as a part of our industry-academia collaborative project between the Company and Osaka University. By combining inexpensive copper salts with Grignard reagents, the desired coupling products are obtained in high yields at ambient temperature. The present method avoids cryogenic conditions (-80℃), a pending issue in the conventional methods, thereby enables the large-scale production of APIs of this category in a more efficient and economical manner.

Tokuyama will continue to engage in the development of competitive manufacturing technologies for APIs in an effort to supply technologies and products that can contribute to the health and high quality of life of people throughout the world.

https://www.cphi.com/europe/en/pharma-awards-2022.html